Cadonilimab Targets PD-1/PD-L1 Blockade-Refractory MSI-H/dMMR Colorectal Cancer
Cadonilimab, a bispecific anti-PD-1/CTLA-4 antibody, is being evaluated for advanced colorectal cancer patients who are refractory to PD-1/PD-L1 blockade.
Asset / Drug
Drug and asset intelligence for Cadonilimab with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.